Shire could 'tolerate' one more acquisition, CEO says

Outsourcing development has allowed Shire to grow to $2.9 billion in revenues with only 5,000 employees worldwide, CEO Angus Russell tells This is Money. Report

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.